ReviewBrain sciences2023
Current Advances in Papillary Craniopharyngioma: State-Of-The-Art Therapies and Overview of the Literature.
Review in Brain sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Modern treatment of craniopharyngioma to improve outcomes: evidence of a change of paradigm.Endocrine · 2025Pooled it
- Advancing Craniopharyngioma Management: A Systematic Review of Current Targeted Therapies and Future Perspectives.International journal of molecular sciences · 2024Pooled it
- Multidisciplinary Management of Pediatric Craniopharyngioma: From Diagnosis to Long-Term Outcomes.Biomedicines · 2026Review
- Early Findings from the Multicenter RAPID Consortium on Papillary Craniopharyngiomas.Journal of neurological surgery. Part B, Skull base · 2026Article
- Management of Anterior Third Ventricular Tumors: A Comprehensive Review and Clinical Experience.Advances and technical standards in neurosurgery · 2026Review
- Aggressive pituitary tumors and pituitary carcinomas: Definition, management, and overview for clinical practice.Neuro-oncology advances · 2025Article
- Molecular subtypes of adamantinomatous craniopharyngiomas.Neuro-oncology · 2025Review
- Population-based histologic analysis of craniopharyngioma demographics and treatment in the US from 2000 to 2020.Journal of neuro-oncology · 2025Article
- Rathke cleft cyst with squamous metaplasia and activating mutations of mitogen-activated protein kinase signaling: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Recent advances in craniopharyngioma pathophysiology and emerging therapeutic approaches.Frontiers in endocrinology · 2025Review
- Development and validation of a radiomics nomogram for preoperative prediction of BRAFNeurosurgical review · 2024Article
- Update on Neoadjuvant and Adjuvant BRAF Inhibitors in Papillary Craniopharyngioma: A Systematic Review.Cancers · 2024Review
- Review
- Adamantinomatous craniopharyngioma: evolution in the management.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Review
- Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma.Pituitary · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Craniopharyngiomas are commonly classified as low-grade tumors, although they may harbor a malignant behavior due to their high rate of recurrence and long-term morbidity. Craniopharyngiomas are classically distinguished into two histological types (adamantinomatous and papillary), which have been recently considered by the WHO classification of CNS tumors as two independent entities, due to different epidemiological, radiological, histopathological, and genetic patterns. With regard to papillary craniopharyngioma, a BRAF V600 mutation is detected in 95% of cases. This genetic feature is opening new frontiers in the treatment of these tumors using an adjuvant or, in selected cases, a neo-adjuvant approach. In this article, we present an overview of the more recent literature, focusing on the specificities and the role of oncological treatment in the management of papillary craniopharyngiomas. Based on our research and experience, we strongly suggest a multimodal approach combining clinical, endocrinological, radiological, histological, and oncological findings in both preoperative workup and postoperative follow up to define a roadmap integrating every aspect of this challenging condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.